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Abstract 52 
 53 
Background: The burden of alcohol-associated cirrhosis (AC) is high, and though alcohol 54 
cessation improves mortality, many patients fail to engage in alcohol use (AUD) treatment and 55 
continue drinking. Our aim was to determine rates, predictors, and outcomes of AUD treatment 56 
utilization in AC patients with private insurance.  Methods: We collected data from persons with 57 
AC (diagnosed by ICD-9/ICD-10 codes), ages 18-64, enrolled in the Truven MarketScan 58 
Commerical Claims and Encounters database (2009-2016).  We determined rates and 59 
predictors of substance abuse treatment visits as well as rates of alcohol relapse prevention 60 
medication prescriptions, weighted to the national employer-sponsored insured population. 61 
Effects of AUD treatment utilization on decompensation rates were calculated using proportional 62 
hazards regression with propensity score adjustment.  Results: 66,053 AC patients were 63 
identified, 32% female, mean age at diagnosis was 54.5 years. 72% had insurance coverage for 64 
substance abuse treatment.  Overall, AUD treatment utilization rates were low, with only 10% 65 
receiving a face-to-face mental health or substance abuse visit and only 0.8% receiving an 66 
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FDA-approved relapse prevention medication within 1 year of index diagnosis.  Women were 67 
less likely to receive a face-to-face visit (HR 0.84, p<0.001) or a FDA-approved relapse 68 
prevention medication (0.89, p=0.05) than men.  AC patients who had a clinic visit for AUD 69 
treatment or used FDA-approved relapse medication showed decreased risk of decompensation 70 
at 1 year (HR 0.85, p<0.001 for either).  Conclusions:  AUD treatment utilization is associated 71 
with lower decompensation rates among privately insured patients with AC.  Women were less 72 
likely to utilize AUD treatment visits.  Efforts to reduce gender-specific barriers to treatment are 73 
urgently needed to improve outcomes. 74 
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Alcohol-associated liver disease (ALD) is a spectrum of liver damage caused by heavy alcohol 100 
use over time, ranging from bland hepatic steatosis, to more severe forms of liver damage, such 101 
as acute alcoholic hepatitis (AAH) and alcohol-associated cirrhosis (AC) (O'Shea et al., 2010; 102 
Schwartz and Reinus, 2012).  The health care and economic burden of ALD is high, both in the 103 
United States (US) and worldwide, where AC is estimated to be reponsible for nearly half the 104 
liver-related deaths (Rehm, Samokhvalov and Shield, 2013; Mellinger, Shedden, et al., 2018). In 105 
the US, AC comprises over half the total costs of cirrhosis amongst the privately insured and is 106 
a major reason for liver transplantation (O'Shea et al., 2010; Goldberg et al., 2017; Mellinger, 107 
Shedden, et al., 2018). Ongoing alcohol use is the strongest predictor of mortality in ALD 108 
patients, particularly those with alcoholic hepatitis (AH) (Louvet et al., 2016).   Between 2002 109 
and 2013, the prevalence of past 12-month alcohol use disorder (AUD) in the US increased 110 
49.4% (Grant et al., 2017). Alcohol use is also increasing worldwide, and in the US, alcohol-111 
related mortality is increasing (World Health Organization, 2014; Dwyer-Lindgren et al., 2018). 112 
Given that AC develops only after years of heavy alcohol use, these increases may result in 113 
rising AC morbidity and mortality(Guirguis et al., 2015). Alcohol cessation is the primary 114 
intervention which arrests and, in some cases, reverses ALD (Thiele et al., 2018).  Yet utilization 115 
and effectiveness of AUD treatment in this population are poorly described.  116 
 117 
Behavioral and medication-related therapies for AUD are well-studied in the general population, 118 
with moderate effect sizes demonstrated in multiple trials, though little evidence to suggest one 119 
treatment modality is superior to another across all population categories(Jonas et al., 2014; 120 
Klimas et al., 2014; Donoghue et al., 2015). For example, in the general population, the number-121 
needed-to-treat (NNT) to prevent a return to any drinking for acamprosate was 12 and for oral 122 
naltrexone was 20 (Jonas et al., 2014).  Despite documented benefits, access to AUD treatment 123 
in the general population is low, with recent large-scale epidemiologic surveys showing a 124 
treatment utilization rate of 7.7% for past year AUD, and 19.8% for lifetime AUD (Hasin and 125 
Grant, 2015). Individuals with AUD that do seek treatment tend to be older (≥ 30 years-old), are 126 
more likely to be men, report more severe and longer histories of substance use problems, and 127 
have co-occurring mood disorders(S. Khan et al., 2013). There are various reasons individuals 128 
with AUD forgo treatment(Greenfield et al., 2007; S. Khan et al., 2013).  Structural barriers such 129 
as lack of insurance coverage are experienced by both men and women (Verissimo and Grella, 130 
2017).  Women, however, report more attitudinal barriers, more perceived stigma and financial 131 
problems, as well as conflicting family and child care responsibilities (Green, Rockhill and 132 
Furrer, 2009; S. Khan et al., 2013; Verissimo and Grella, 2017).  133 
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 134 
Utilization of AUD treatment in patients with ALD has been less well evaluated.  A recent 135 
systematic review of psychosocial, abstinence-focused treatments for AUDs among patients 136 
with chronic liver disease found only five randomized controlled trials in the literature, three of 137 
which included AC patients exclusively (Kuchipudi et al., 1990; Willenbring and Olson, 1999; 138 
Weinrieb et al., 2011; A. Khan et al., 2016). Only one randomized controlled trial of combined 139 
motivational enhancement therapy and cognitive-behavioral therapy embedded in the medical 140 
clinic showed significantly higher rates of abstinence in the treatment group compared to 141 
controls (Willenbring and Olson, 1999). In terms of medication-based treatments, research in 142 
AC patients is even more scarce, with only a single randomized trial of baclofen, an off-label 143 
relapse prevention medication, demonstrating a two-fold increase in abstinence among 42 AC 144 
patients receiving baclofen for 12 weeks versus placebo (Addolorato et al., 2007).  145 
 146 
Given the clearly established benefits of alcohol cessation in AC patients and the dearth of 147 
research on treatment utilization, the aims of our study were to: 1) assess the rates and 148 
predictors of AUD treatment utilization among adults with AC in a large, nationally-149 
representative dataset of privately insured Americans; and 2) determine if utilization of AUD 150 
treatment is associated with improved clinical outcomes.  151 
  152 
Materials and Methods 153 
Population  154 
The cohort of AC patients was drawn from the Truven Analytics Marketscan Commercial Claims 155 
and Encounters (CCAE) database from 2009-2016.  In the US, private insurance accounts for 156 
approximately 50% of the total insurance market, with the overwhelming majority of privately 157 
insured individuals receiving coverage via their employer.  Marketscan compiles claims from 158 
>100 million employed persons and their dependents across all regions of the US, representing 159 
well over 50% of the employer sponsored insurance market.  Marketscan data includes claims 160 
for enrollees across inpatient, outpatient, facility, and pharmaceutical claims and has been used 161 
in multiple large-scale medical and surgical studies of healthcare delivery and costs (Mellinger, 162 
Shedden, et al., 2018).  163 
  164 
Inclusion Criteria and Alcoholic Cirrhosis Case Ascertainment 165 
The initial dataset included all patients from 2009-2016, ages 18-64, who had at least a single 166 
ICD-9 or ICD-10 code for cirrhosis and at least 1 year of continuous enrollment, including the 167 
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index cirrhosis diagnosis date (see Appendix A).  Age was capped at 64 given that most 168 
patients age 65 and older transition onto Medicare and are thus lost from the dataset.  All data 169 
were restricted to the continuous enrollment period containing the cirrhosis diagnosis.  AC was 170 
defined using previously published criteria as a single ICD-9 or ICD-10 code for alcohol-171 
associated cirrhosis or a code for cirrhosis without mention of alcohol plus a code for alcohol 172 
use or an alcohol-related comorbidity (see Appendix A)(Beste et al., 2015; Mellinger, Shedden, 173 
et al., 2018).  Patients with both AC and hepatitis C (HCV) codes were counted as having AC.  174 
Cirrhosis-related complications, such as ascites and hepatic encephalopathy, were defined by 175 
ICD-9 or ICD-10 codes (see Appendix A).  Decompensated AC was defined as an AC diagnosis 176 
code and a diagnosis code for a portal hypertensive complication (ascites, hepatic 177 
encephalopathy, or variceal bleeding).  Single diagnosis codes for cirrhosis and for portal 178 
hypertensive complications have been validated in administrative data and found to have 179 
positive predictive values of 80% or greater (Kramer et al., 2008; Nehra et al., 2013).  Medical 180 
comorbidities were estimated using the Elixhauser comorbidity scale with the liver disease and 181 
alcohol abuse categories excluded as these were accounted for separately in our models 182 
(Elixhauser et al., 1998). An indicator variable for whether or not the enrollee had insurance 183 
coverage for mental health and substance abuse (MHSA) care was included.  Census regions 184 
were used as geographic variables for predictors of AUD treatment access with census region 3 185 
(South) as the reference region.   186 
  187 
Mental Health and Substance Abuse (MHSA) Treatment Ascertainment  188 
We defined comorbid depression or anxiety by ICD-9 or ICD-10 codes.  Because substance use 189 
is frequently assessed and treated alongside other mental health issues and is often comorbid 190 
with alcohol use and misuse, alcohol use treatment was defined as either a substance use or 191 
mental health outpatient visit or a prescription for a US Food and Drug Administration (FDA) 192 
approved alcohol relapse prevention medication.  We performed additional analyses of non-193 
FDA approved alcohol relapse prevention medications.  A mental health/substance abuse 194 
(MHSA) treatment visit was defined as a Current Procedural Terminology (CPT) code for a face-195 
to-face outpatient visit combined with a claims-based service category code indicating a 196 
substance abuse related claim was submitted on the same day or a CPT code for a face-to-face 197 
outpatient visit with a provider code indicating that the visit was conducted by a psychiatrist or 198 
psychologist.  FDA-approved (disulfiram, naltrexone, and acamprosate) and non-FDA approved 199 
medications (baclofen, gabapentin, and topiramate) for alcohol relapse prevention were 200 
identified in the pharmaceutical claims dataset.  Enrollees were required to have a 90-day or 201 
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greater continuous prescription in order to eliminate short courses of treatment which would be 202 
expected to have less influence on alcohol use. Analyses of medication prescriptions were 203 
restricted to enrollees with prescription drug coverage.  204 
  205 
Statistical Methods  206 
We calculated baseline proportions of covariates present at index diagnosis.  AC, HCV, and 207 
diabetes were treated as time invariant, meaning that if a diagnosis appeared at any time in the 208 
enrollment period, enrollees were counted as having these diagnoses.  We calculated pre- and 209 
post-index cirrhosis diagnosis rates of MHSA treatment utilization. Rates for medication use 210 
(antidepressants, alcohol relapse prevention medications) were calculated in the population of 211 
patients with prescription drug coverage, while rates of MHSA clinic visits were calculated in the 212 
total population with or without prescription drug coverage.  We modelled the cumulative event 213 
rates for major events of interest (prescriptions for FDA or non-FDA approved relapse 214 
prevention medication and MHSA outpatient visits) at 1 month, 1 year, and 2 years post-index 215 
diagnosis and weighted these to reflect the national population with private, employer-216 
sponsored insurance as previously reported (Mellinger, Shedden, et al., 2018).  To identify 217 
predictors of treatment utilization, we used proportional hazards regression with propensity 218 
score adjustment based on multiple covariates and 100 strata to model the hazard from the 219 
index AC diagnosis to the first occurrence of a given form of alcohol use treatment (visit or 220 
medication).  Models were fit using standard methods for proportional hazard estimation in the 221 
setting of time-varying covariates.  Patients who received liver transplant were censored at time 222 
of transplant.  For additional analyses of non-FDA approved relapse prevention medications, 223 
diabetes was considered an independent predictor given the high occurrence of gabapentin use 224 
for diabetic neuropathy. 225 
  226 
Clinical Outcomes 227 
Our primary clinical outcome was hepatic decompensation defined as ascites, hepatic 228 
encephalopathy, or variceal bleeding.  We assessed the association between MHSA treatment 229 
and decompensation using proportional hazards regression with time-varying covariates as in 230 
the above methods for predictors of treatment access.  Patients with decompensation 231 
diagnoses at index diagnosis were excluded from the model.  Propensity score adjustment 232 
based on multiple covariates and 100 strata were used as in the access model above. The 233 
effects of MHSA treatment on decompensation were assessed in three separate models: 1) 234 
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FDA approved medications alone, 2) MHSA treatment visits alone, and 3) FDA approved 235 
medications and MHSA treatment visits as a composite variable.  236 
  237 
Results 238 
  239 
Patient Characteristics 240 
66,053 patients with AC were identified, approximately one-third were female (see Table 1). 241 
Mean age at diagnosis was 53.5 years.  Of these, 72% had MHSA coverage under their 242 
insurance plans and 87% had prescription drug coverage.  Roughly one quarter (28%) also had 243 
HCV and 53% were decompensated.  Depression and anxiety were present in 16% and 12%, 244 
respectively at index cirrhosis diagnosis.  Baseline FDA-approved alcohol relapse prevention 245 
medication prescriptions were rare (0.4%) while non-FDA approved relapse medications were 246 
more common (3.2%).  Gabapentin made up the greatest proportion of non-FDA approved 247 
relapse prevention medication prescriptions at index cirrhosis diagnosis (2.6%) (see Figure 1).     248 
  249 
Rates of AUD Treatment and Alcohol Relapse Prevention Utilization After Index AC Diagnosis 250 
in the National Employer-Sponsored Insurance Population 251 
FDA-approved alcohol relapse prevention medication use and MHSA visits increased over time, 252 
from 0.2% for medications and 3.0% for MHSA visits at 1 month after AC diagnosis to 0.8% and 253 
10.1%, respectively, at 1 year; and to 1.2% and 14.5%, respectively, at 2 years (see Figure 2).  254 
MHSA visits alone accounted for most of the AUD treatment utilization. Rates of FDA-approved 255 
alcohol relapse prevention medications alone were low, increasing from 0.2% at 1 month to 256 
1.2% at 2 years, with similar rates of acamprosate and naltrexone usage and a lower rate of 257 
usage of disulfiram. Use of non-FDA-approved medications that have been suggested to 258 
prevent alcohol relapse was more common, and dominated by gabapentin use (8.3% at 2 years 259 
post-diagnosis).  260 
 261 
Predictors of AUD Treatment Utilization in the MarketScan Population 262 
Women were less likely to utilize face-to-face MHSA clinic visits (HR 0.84, p<0.001) and FDA-263 
approved alcohol relapse prevention medications (HR 0.89, p=0.05) (see Figure 3).  In analyses 264 
of separate outcomes (MHSA visits or FDA-approved relapse prevention medications), patients 265 
with MHSA insurance coverage were more likely to utilize MHSA clinic visits (HR 1.32, p<0.001) 266 
and FDA-approved alcohol relapse prevention medications (HR 1.88, p<0.001) than those who 267 
did not.  Older patients and those with decompensation were less likely to have attended a face-268 
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to-face MHSA clinic visit (HR 0.97 and HR 0.89, p<0.001 for both) while patients with 269 
depression and anxiety diagnoses were much more likely to have such visits (HR 2.17 and HR 270 
1.47, p<0.001 for both).  See Table 2 for findings from the composite outcome of either MHSA 271 
visit or FDA approved relapse prevention medicine.  272 
 273 
Within the cohort of AC patients with prescription drug coverage, women were less likely to 274 
receive FDA-approved alcohol relapse prevention medication prescriptions (HR 0.89, p=0.05) 275 
than men and those with MHSA insurance coverage were more likely to receive these 276 
prescriptions (HR 1.88, p<0.001) than those without MHSA insurance coverage.  Having a 277 
depression diagnosis was the strongest predictor of FDA-approved alcohol relapse prevention 278 
medication utilization (HR 3.62, p<0.001) as was having an anxiety diagnoses though the effect 279 
was attenuated compared to depression (HR 1.32, p<0.001).  In additional analyses examining 280 
utilization of non-FDA approved relapse prevention medications, women were more likely to 281 
receive these prescriptions as well even after discounting gabapentin use (any non-FDA 282 
medication: HR 1.33, p<0.001; topiramate and baclofen only (no gabapentin): HR 1.84, 283 
p<0.001).      284 
 285 
Clinical Outcome: Hepatic Decompensation in the MarketScan Population 286 
Approximately one-fifth (19%) of patients had new diagnosis codes for hepatic decompensation 287 
within 1 year after index diagnosis of AC. In multivariate models, utilization of an MHSA clinic 288 
visit alone had a protective effect on risk of decompensation (HR 0.89, p<0.001).  Although the 289 
number was small, use of FDA-approved alcohol relapse prevention medication alone had a 290 
greater effect on decreasing the risk of decompensation (HR 0.65, p<0.001). In a composite 291 
model analyzing effects of having either an MHSA visit or an FDA-approved relapse medication, 292 
reduction in risk of decompensation was similar to that of MHSA visit alone likely due to 293 
infrequent use of FDA-approved relapse medication (HR 0.85, p<0.001) (see Table 3).  Older 294 
age was associated with a minimally lower risk of decompensation (HR 0.998, p<0.001). There 295 
was a gender and Elixhauser interaction resulting in slightly lower risk of decompensation (HR 296 
0.96, p<0.001). Diagnoses of depression and use of antidepressant medications were both 297 
associated with lower rates of hepatic decompensation (HR 0.77 and HR 0.99, p<0.001 for 298 
both).  In both models of MHSA visits and FDA medications, primary care visits were associated 299 
with decreased risk for decompensation (HR 0.82 and 0.83, p<0.001 for both). 300 
 301 
Discussion 302 
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 303 
In this large study of privately insured patients with AC, overall utilization of AUD treatment was 304 
low, despite a high rate of MHSA insurance coverage. Gender influenced utilization, with 305 
women being less likely to obtain both a face-to-face MHSA clinic visit and FDA-approved 306 
relapse prevention medications. Those who utilized alcohol use treatment, whether men or 307 
women, were significantly less likely to decompensate at one year after index diagnosis 308 
compared to those who did not utilize such treatment, even when adjusting for comorbidities, 309 
such as hepatitis C and diabetes.  In a best-case scenario, men and women who access AUD 310 
treatment early, whether relapse prevention medications or MHSA clinic visits may avoid 311 
progression to AC and decompensation with its subsequent high mortality and possible need for 312 
transplant.  Those who fail to access AUD treatment and continue drinking, may go on to further 313 
decompensate, bringing with it higher mortality, more inpatient hospital admissions, higher 314 
costs, and potential need for transplant.  For those that don’t access formal AUD treatment, 315 
transplant may be denied given the requirement for alcohol cessation and formal AUD treatment 316 
at most US liver transplant centers.  317 
 318 
Similar to reported low rates of MHSA utilization in the general population, only 10% of privately 319 
insured AC patients utilized a MHSA clinic visit within 1 year after their index diagnosis.  While 320 
lack of insurance coverage is frequently cited as a major reason for lack of utilization of AUD 321 
treatment, our study population had private insurance with a high rate of MHSA coverage, and 322 
MHSA coverage was weakly correlated with utilization.  This fits with existing data showing that 323 
barriers to AUD treatment are related more to patient attitudes than to structural insurance 324 
issues (S. Khan et al., 2013; Verissimo and Grella, 2017).  The gender imbalance in alcohol 325 
treatment utilization in the privately insured AC population is consistent with research in the 326 
broader AUD population indicating women are less likely to receive inpatient, outpatient, 327 
emergency room, or other face-to-face treatment for AUD relative to men and are less likely to 328 
attend specialty addiction treatment services (S. Khan et al., 2013). In a mixed-methods study of 329 
AC patients, men and women identified attitudinal barriers as major causes for lack of AUD 330 
treatment uptake (Mellinger, Scott Winder, et al., 2018).  331 
 332 
Barriers to AUD treatment differ between men and women with women experiencing more 333 
barriers relative to men, including higher perceived stigma and other ‘attitudinal’ barriers as well 334 
as higher economic and time barriers (Green, Rockhill and Furrer, 2009; S. Khan et al., 2013; 335 
Verissimo and Grella, 2017). Diagnosis of AUDs in women is challenging as alcohol screening 336 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
tools have lower specificity among women and opportunites for diagnosis are frequently missed 337 
(Volk et al., 1997; Bradley et al., 1998). For example, amongst AC patients in the UK, women 338 
were less likely to have alcohol use recorded and were overall less likely to interact with the 339 
healthcare system in the period prior to their AC diagnosis (Otete et al., 2015).  Despite 340 
evidence that women are less likely to seek face-to-face treatment, when women do access 341 
psychosocial treatment, they may have better treatment outcomes than men (Green, Rockhill 342 
and Furrer, 2009; Sugarman et al., 2017).  Low treatment utilization among women is 343 
particularly concerning given a higher proportion of American women now meet criteria for AUD 344 
than ever before, with rates rising more rapidly in women than in men (Grant et al., 2017).  In 345 
the liver disease population, women frequently develop AC and alcoholic hepatitis at lower 346 
amounts of alcohol consumed and shorter time-frames compared to men, suggesting that rates 347 
of ALD, as demonstrated in our earlier study, will rise more rapidly in women, increasing the 348 
urgency for connection to professional AUD treatment (Nielsen et al., 2017; Mellinger, Shedden, 349 
et al., 2018; Szabo, 2018).   350 
 351 
We found that only a very small fraction (0.8%) of AC patients received an FDA-approved 352 
relapse prevention medication despite having insurance coverage for healthcare and 353 
prescriptions. It is possible that this under-utilization of is related to concerns about liver toxicity 354 
for naltrexone and disulfiram.  Acamprosate, which is not metabolized by the liver, has no 355 
reported instances of clinically significant hepatotoxicity and may be safe, but it has not been 356 
explicitly tested in those with advanced liver disease.  Only baclofen, a non-FDA approved 357 
relapse prevention medication, has been tested in a small randomized trial in patients with AC, 358 
showing a benefit at 12 weeks of treatment with baclofen 10 mg three times daily with an 359 
acceptable side effect profile (Addolorato et al., 2007).  In our study, baclofen use, like other 360 
relapse prevention medications, was low.   361 
 362 
We found that a 90 day prescription for an FDA-approved alcohol relapse prevention medication 363 
was associated with an even greater reduction in decompensation compared to an MHSA clinic 364 
visit.  While our findings do not demonstrate causation, given alcohol’s deleterious effects on 365 
cirrhosis and portal hypertensive complications, one possible mechanism for their positive 366 
influence may be via improved rates of alcohol abstinence, similar to the mechanism for MHSA 367 
visit effect (Lucey et al., 2008).  Our additional analyses indicated that non-FDA approved 368 
relapse prevention medications also had a large effect on decompensation rates.  Gabapentin, 369 
a neuromodulator typically prescribed for seizures or peripheral neuropathy, has an increasing 370 
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literature base supporting its effects on relapse prevention, primarily through modulation of 371 
alcohol craving, and was the most common relapse prevention medication prescribed, though it 372 
is likely much more frequently prescribed for other indications such as neuropathy (Mason et al., 373 
2014). Similarly, topiramate has some evidence, though with smaller studies, for reducing 374 
alcohol use (Johnson et al., 2003; 2007).  While the indication for use of gabapentin, topiramate 375 
and baclofen in our patient population cannot be determined, the associated beneficial effect on 376 
decompensation rates is worthy of further study.   377 
 378 
Diagnoses of depression and anti-depressant medication use were associated with increased 379 
utilization of MHSA care (both visits and FDA-approved relapse medications) and lower rates of 380 
decompensation.  This effect may be related to the fact that patients diagnosed with depression 381 
or anxiety and prescribed anti-depressant medications to treat these conditions are connected 382 
to the medical system and likely utilize care overall to a greater degree.  Comorbid mental 383 
illness is common in AUD patients and associated with increased, though inconsistent, 384 
utilization of primary medical care (Ford et al., 2005).  The complex psychosocial milieu and 385 
medical comorbidities AC patients confront combined with complex medication prescribing in 386 
advanced liver disease, warrant the establishment of integrated clinics with co-located 387 
substance use professionals working alongside hepatologists to appropriately care for these 388 
complex patients.          389 
 390 
There were several limitations to our study.  First, this database only assesses those with 391 
private insurance and a claim for healthcare services and may thus lack generalizability to non-392 
privately insured populations.   Second, alternate supports for sobriety in the community, such 393 
as mutual aid societies like Alcoholics Anonymous, would not be reflected in our data and are 394 
difficult to measure.  Third, behavioral interventions for alcohol treatment, such as 395 
psychoeducation or other brief interventions, are frequently delivered by non-addiction 396 
specialists and may have occurred outside MHSA visits.  We attempted to mitigate this limitation 397 
by broadening our ascertainment to include both visits conducted by a psychiatrist or 398 
psychologist as well as visits where a service category code related to substance abuse 399 
treatment was entered, regardless of the specialty of the medical provider entering the code.  400 
Fourth, we are unable to determine the content of the substance abuse intervention and cannot 401 
ascertain the effectiveness of different modalities of alcohol use treatment. Fifth, AUD treatment 402 
efficacy may be influenced by endogenous factors influencing a patient’s motivation to take up 403 
alcohol treatment such that patients who engage in treatment are more likely to stop drinking for 404 
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reasons other than the treatment effectiveness.  Sixth, the requirement for 1 year of continuous 405 
enrollment may have biased the population towards a healthier population by excluding those 406 
who died within 1 year of diagnosis or lost insurance due to disability. 407 
  408 
In conclusion, patients with AC utilize AUD treatment at low rates within 1 year after AC 409 
diagnosis, with women less likely to receive AUD treatment compared to men.  Alcohol 410 
cessation is the only intervention known to improve mortality in patients with ALD , and receipt 411 
of AUD treatment in our study was significantly associated with improved outcomes.  As such, 412 
efforts to improve utilization rates of MHSA care, including treatment of comorbid mental health 413 
conditions, are necessary.  Integrated care combining professional mental health and 414 
hepatology care as well as the development of novel behavioral treatments for this population 415 
are urgently needed.  416 
 417 
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Figure 1. Proportion of alcohol relapse prevention medication prescriptions at index diagnosis, 549 
by type of prescription.  550 
 551 
Figure 2.  Rates of MHSA treatment utilization at 1 month, 1 and 2 years post index diagnosis. 552 
 553 
Figure 3. Gender differences in MHSA treatment utilization. 554 
 555 
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Table 1. Population characteristics at index alcoholic cirrhosis diagnosis. 
 
Characteristics 
Total AC patients 
n=66053 
N (%) 
Female 21442 (32%) 
Mean age (years) 53.5 
Mental Health/ Substance Abuse 
Treatment Coverage 
47505 (72%) 
Prescription Drug Coverage 57,632 (87%) 
Mean Elixhauser 3.53 
Hepatitis C 18817 (28%) 
Decompensation* 35069 (53%) 
Anxiety 7642 (12%) 
Depression 10652 (16%) 
Any FDA Approved Alcohol Relapse 
Prevention Medication 
275 (0.4%) 
Acamprosate 122 (0.2%) 
Disulfiram 133 (0.2%) 
Naltrexone 99 (0.1%) 
 *Decompensation defined as presence of ascites, variceal bleeding,  
or hepatic encephalopathy 
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Table 2.  Predictors of access to MHSA visits or FDA alcohol relapse prevention medications 
Variable Hazard Ratio  
(95% Confidence Interval) 
P Value 
MHSA Insurance Coverage 1.34 (1.28-1.40) <0.001 
Female 0.85 (0.82-0.88) <0.001 
Decompensated Cirrhosis 0.89 (0.86-0.92) <0.001 
Diabetes  0.79 (0.76-0.82) <0.001 
Age at diagnosis 0.97 (0.97-0.98) <0.001 
Hepatitis C 1.00 (0.97-1.04) 0.70 
Anxiety 1.47 (1.41-1.53) <0.001 
Depression 2.21 (2.13-2.30) <0.001 
Elixhauser 1.41 (1.37-1.44) <0.001 
PCP Visit 1.60 (1.54-1.67) <0.001 
GI Clinic Visit 1.07 (1.03-1.11) <0.001 
South* 1.00 * 
Northeast 1.33 (1.27-1.39) <0.001 
Midwest 1.20 (1.15-1.26) <0.001 
West 1.53 (1.46-1.60) <0.001 
*indicates reference category census region  
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Table 3.  Substance abuse treatment utilization effects on occurrence of hepatic 
decompensation within 1 year following index cirrhosis diagnosis. 
Variable HR (95% Confidence Interval) P value 
Composite MHSA Visit and/or FDA medication 0.85 (0.82-0-.87) <0.001 
Female: Elixhauser 0.96 (0.94-0.97) # <0.001 
Diabetes 0.98 (0.96-0.99) <0.001 
Age at diagnosis 0.998 (0.998-0.999) 0.02 
HCV 1.22 (1.20-1.24) <0.001 
Hepatorenal Syndrome 2.63 (2.51-2.76) <0.001 
Acute Kidney Injury 1.37 (1.34-1.40) <0.001 
Infection 1.16 (1.14-1.18) <0.001 
Depression 0.77(0.76-0.79) <0.001 
Anti-depressant medication prescription 0.99 (0.97-1.01) <0.001 
PCP Visit 0.83 (0.82-0.84) <0.001 
GI Visit 1.36 (1.35-1.38) <0.001 
South* 1.00 * 
Northeast 0.95 (0.93-0.97) <0.001 
Midwest 1.03 (1.01-1.05) 0.002 
West 1.06 (1.04-1.08) <0.001 
 #
*Indicates reference category for geographic comparisons    
Interaction between gender and Elixhauser score   
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